Genmab A/S
GMABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Genmab A/S focuses on Biotechnology services and products. Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. Valued at $20.61B, GMAB is a large-cap name in its sector. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Market Cap
$20.61B
Beta
0.70
P/E (TTM)
26.61
P/E (Fwd)
21.09
EPS (TTM)
$1.26
EPS (Fwd)
$1.59
ROE
14.0%
ROA
8.8%
Cash
$1.51B
Total Debt
$5.27B
Free CF
$870.6M
52W Change
21.2%
Annual Financials
Cash vs Debt
Where GMAB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GMAB finished 20.79% above its 150-day moving average ($28.33) and 16.75% above its 200-day moving average ($29.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GMAB overbought or oversold?
At the September 3, 2026 close, GMAB's RSI(14) was 67.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Genmab A/S carries $5.27B in total debt against $1.51B in cash reserves — debt is roughly 3.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $870.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 14.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.09B (2022) to $3.72B (2025), reflecting a 78% increase over the period.
The relatively low beta of 0.70 suggests GMAB is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing GMAB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.